The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure.
The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure.
复制标题
山楂特殊提取物 WS 1442 对轻度至中度心力衰竭症状患者临床进展的影响。
DOI：
10.1016/j.ejheart.2008.04.008
复制
发表时间：
2008
影响因子：
18.2
通讯作者：
Aaronson,KeithD
中科院分区：
文献类型：
--
作者：
Zick,SuzannaM;Gillespie,Brenda;Aaronson,KeithD
AimTo examine whether hawthorn (CrataegusSpecial Extract WS 1442 {CSE}) inhibits progression in heart failure (HF) patients.MethodsWe performed a retrospective analysis of data from the HERB CHF study in which patients with mild to moderate HF were randomised to either CSE 900 mg or placebo for 6months. The primary outcome was time to progression of HF (HF death, hospitalisation, or sustained increase in diuretics) as assessed by log‐rank tests and by Cox modelling.ResultsProgression of HF occurred in 46.6% of the CSE and 43.3% of the placebo groups (OR 1.14, 95% CI=0.56, 2.35:p=0.86). Patients receiving CSE were 3.9 times (95% CI=1.1−13.7:p=0.035) more likely to experience HF progression at baseline. In adjusted analysis, the risk of having early HF progression in the CSE group increased to 6.4 (95% CI=1.5, 26.5:p=0.011). In patients with LVEF≤35%, those taking CSE were at significantly greater risk (3.2, 95% CI=1.3, 8.3:p=0.02) than the placebo group.ConclusionsCSE does not reduce heart failure progression in patients who have HF. CSE appears to increase the early risk of HF progression.
